title: A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.
abstract: In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.
authors.affiliation: Department of Psychiatry, New York University Medical Center, NY 10016.
authors.forename: C
authors.initials: C
authors.lastname: Flicker
authors.forename: S H
authors.initials: SH
authors.lastname: Ferris
authors.forename: D
authors.initials: D
authors.lastname: Kalkstein
authors.forename: M
authors.initials: M
authors.lastname: Serby
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005732:Gangliosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000502:physiology; D009483:Neuropsychological Tests; D010919:Placebos; D013268:Stimulation, Chemical; D016896:Treatment Outcome
chemical_list: D005732:Gangliosides; D009414:Nerve Growth Factors; D010919:Placebos; C025447:sialogangliosides